<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04889677</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-001</org_study_id>
    <nct_id>NCT04889677</nct_id>
  </id_info>
  <brief_title>Study of a Single Dose of Danicopan in Healthy Participants</brief_title>
  <official_title>A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of ACH 0144471 In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a single ascending dose, randomized, double-blind study assessing the safety,&#xD;
      tolerability, pharmacokinetics, and pharmacodynamics of danicopan in healthy participants.&#xD;
      Four different doses (200 milligrams [mg], 600 mg, 1200 mg, 2400 mg) and dose-matched placebo&#xD;
      were administered under fasted and fed conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 4, 2016</start_date>
  <completion_date type="Actual">June 21, 2016</completion_date>
  <primary_completion_date type="Actual">June 21, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Of Serious Adverse Events, Grade 3 Or 4 Adverse Events (AEs), AEs Leading To Discontinuation, And Clinically Significant Laboratory Abnormalities And Electrocardiogram Abnormalities</measure>
    <time_frame>Day 1 through Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under The Plasma Concentration-time Curve Extrapolated To Infinity (AUC0-inf) Of Danicopan Under Both Fed And Fasted Conditions</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Plasma Concentration (Cmax) Of Danicopan Under Both Fed And Fasted Conditions</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Reach The Maximal Plasma Concentration (Tmax) Of Danicopan Under Both Fed And Fasted Conditions</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Alternative Pathway Inhibition And Danicopan Plasma Concentrations</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1: 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants (fasted) received either 200 mg of danicopan as a single oral dose or dose-matched placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants (fasted) received either 600 mg of danicopan as a single oral dose or dose-matched placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants (fasted) received either 1200 mg of danicopan as a single oral dose or dose-matched placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: 2400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants (fasted) received either 2400 mg of danicopan administered as 2 single doses of 1200 mg each, 12 hours apart, or dose-matched placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants (fed) received either 1200 mg of danicopan as a single oral dose or dose-matched placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan</intervention_name>
    <arm_group_label>Group 1: 200 mg</arm_group_label>
    <arm_group_label>Group 2: 600 mg</arm_group_label>
    <arm_group_label>Group 3: 1200 mg</arm_group_label>
    <arm_group_label>Group 4: 2400 mg</arm_group_label>
    <arm_group_label>Group 5: 1200 mg</arm_group_label>
    <other_name>ACH-0144471 (formerly)</other_name>
    <other_name>ALXN2040</other_name>
    <other_name>ACH-4471</other_name>
    <other_name>ACH4471</other_name>
    <other_name>4471</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group 1: 200 mg</arm_group_label>
    <arm_group_label>Group 2: 600 mg</arm_group_label>
    <arm_group_label>Group 3: 1200 mg</arm_group_label>
    <arm_group_label>Group 4: 2400 mg</arm_group_label>
    <arm_group_label>Group 5: 1200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy defined as having no clinically relevant abnormalities identified by a&#xD;
             detailed medical history, physical examination, blood pressure and pulse rate&#xD;
             measurements, 12-lead electrocardiogram, and clinical laboratory tests.&#xD;
&#xD;
          -  Body mass index of 18 to 30 kilograms (kg)/meter squared with a minimum body weight of&#xD;
             50 kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or clinically relevant evidence of significant cardiovascular, pulmonary,&#xD;
             hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             neurological, or psychiatric disease.&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (for example, gastrectomy),&#xD;
             cholecystectomy to be considered acceptable.&#xD;
&#xD;
          -  Body temperature ≥ 38°Celcius on Day -1 or Day 1 Hour 0; history of febrile illness or&#xD;
             other evidence of infection within 14 days prior to study drug administration.&#xD;
&#xD;
          -  Current tobacco/nicotine users; consumption of any alcohol within 72 hours before&#xD;
             study drug administration or a history of regular alcohol consumption exceeding 21&#xD;
             drinks/week within 6 months of Screening; positive urine drug screen at Screening or&#xD;
             Day -1.&#xD;
&#xD;
          -  Clinically significant laboratory abnormalities at either Screening or Day -1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <results_reference>
    <citation>Wiles JA, Galvan MD, Podos SD, Geffner M, Huang M. Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471). Curr Med Chem. 2020;27(25):4165-4180. doi: 10.2174/0929867326666191001130342. Review.</citation>
    <PMID>31573880</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Danicopan</keyword>
  <keyword>ALXN2040</keyword>
  <keyword>ACH-0144471</keyword>
  <keyword>Factor D Inhibitor</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Ascending Dose</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

